Lu Wenhao, Arthur Vithran Djandan Tadum, Jallow Bubacarr, Jiang Shide, Li Yusheng, Wei Licheng, Xiao Wenfeng
EFORT Open Rev. 2025 Jul 1;10(7):510-519. doi: 10.1530/EOR-2024-0069.
Dexmedetomidine is a widely employed adjunct in nerve block anesthesia for shoulder arthroscopy. This study aimed to assess the analgesic efficacy of dexmedetomidine as a nerve block adjuvant in patients undergoing shoulder arthroscopy.
A thorough search of PubMed/MEDLINE, Embase, Web of Science and the Cochrane Library databases was conducted to identify randomized-controlled trials comparing the effects of dexmedetomidine-enhanced shoulder arthroscopy nerve blocks against those without dexmedetomidine. This systematic review and meta-analysis followed the PRISMA guidelines. The Cochrane-recommended risk of bias tool was employed for quality and bias assessment. Statistical analysis, utilizing Review Manager 5.4 with a significance level of P < 0.05, focused on primary outcomes: duration of analgesia and postoperative 24 h morphine consumption, and secondary outcomes: motor and sensory block duration, visual analog scale pain scores and adverse events.
Out of 307 articles retrieved, ten randomized-controlled trials involving 672 patients were included. Dexmedetomidine supplementation significantly prolonged the duration of analgesia (MD = 3.58, 95% CI: 2.53- 4.63, P < 0.00001, I 2 = 77%) and decreased postoperative morphine consumption (MD = -11.88, 95% CI: -17.25 to -6.52, P < 0.0001, I 2 = 41%). In addition, the dexmedetomidine group exhibited lower VAS pain scores at 1, 12 and 24 h postoperatively. No significant differences were observed in motor block duration, bradycardia (P = 0.18), hypotension (P = 0.50) and nausea and vomiting (P = 0.76). Sensitivity analyses validated the robustness of these findings.
This meta-analysis supports dexmedetomidine as an effective adjuvant in nerve blocks for shoulder arthroscopy. It enhances postoperative analgesia without increasing adverse events such as bradycardia, hypotension and nausea and vomiting.
右美托咪定是肩关节镜检查神经阻滞麻醉中广泛使用的辅助药物。本研究旨在评估右美托咪定作为神经阻滞辅助药物在接受肩关节镜检查患者中的镇痛效果。
全面检索PubMed/MEDLINE、Embase、Web of Science和Cochrane图书馆数据库,以识别比较右美托咪定增强肩关节镜检查神经阻滞效果与未使用右美托咪定效果的随机对照试验。本系统评价和荟萃分析遵循PRISMA指南。采用Cochrane推荐的偏倚风险工具进行质量和偏倚评估。使用Review Manager 5.4进行统计分析,显著性水平为P < 0.05,重点关注主要结局:镇痛持续时间和术后24小时吗啡消耗量,以及次要结局:运动和感觉阻滞持续时间、视觉模拟量表疼痛评分和不良事件。
在检索到的307篇文章中,纳入了10项涉及672例患者的随机对照试验。补充右美托咪定显著延长了镇痛持续时间(MD = 3.58,95%CI:2.53 - 4.63,P < 0.00001,I² = 77%),并减少了术后吗啡消耗量(MD = -11.88,95%CI:-17.25至-6.52,P < 0.0001,I² = 41%)。此外,右美托咪定组在术后1、12和24小时的VAS疼痛评分较低。在运动阻滞持续时间、心动过缓(P = 0.18)、低血压(P = 0.50)以及恶心和呕吐(P = 0.76)方面未观察到显著差异。敏感性分析验证了这些发现的稳健性。
本荟萃分析支持右美托咪定作为肩关节镜检查神经阻滞的有效辅助药物。它增强了术后镇痛效果,而不会增加诸如心动过缓、低血压以及恶心和呕吐等不良事件的发生。